Kenny Walter

Gestational age and NICU admission both were associated with the risk of developing EoE.

Investigators examined data on abrocitinib from the JADE REGIMEN study.

Itch intensity was highest at bedtime compared to all other time periods of the day.

Patients with allergic asthma could often have no clinical history of atopic dermatitis.

In data presented at AAAAI 2022, investigators examined anaphylaxis rates in Brooklyn between 2016-2019.

Investigators from the Cincinnati Children’s Hospital Medical Center tested a new allergic reaction severity grading system.

The most common burden of disease were itching, dry or rough skin, and cracked skin.

Those who were breastfed for less than 4 months also had lower risks of developing atopic diseases.

Urticaria and angioedema with oral mucocutaneous involvement were commonly labeled as anaphylaxis upon presentation.

The proportion of anaphylaxis episodes was higher in the cohort of patients with peanut allergies, compared to a control group of patients with non-peanut food allergies.

Data supporting BI 1015550 as a IPF therapy will be presented at the upcoming ATS meeting.

Obesity was added to the list of risk factors for influenza in 2009.

The most frequent trajectory for children with insomnia symptoms was persistence, followed by remission and waxing-and-waning patterns.

Daridorexant 25 mg and 50 mg had the best results in comparison with placebo.

The Supplemental New Drug Application was based on the results of numerous clinical trials.

Melatonin is seen as the most promising treatment in this patient population.

Assessing fat free mass and reduced intake are particularly important in identifying malnutrition in patients with inflammatory bowel disease.

In data presented at ECCO 2022, investigators identified the optimal infliximab cut-off level was 4 μg/ml.

AHN is one of the few hospitals who have implemented this type of program to treat IBD complications.

There is no clinically meaningful differences in safety and efficacy between biologics and biosimilars.

Guselkumab is being studied as a treatment for both Crohn's disease and ulcerative colitis.

The data presented during ECCO 2022 involved IBD patients both in Hong Kong and the US.

There is concerns over missed early screenings for gastrointestinal cancers due to the COVID-19 pandemic.

The efficacy rates at weeks 12 and 52 were numerically lower in ileal only Crohn’s disease relative to colonic only and ileal-colonic.

A higher proportion of patients treated with mirikizumab achieved clinical remission at week 12 compared to placebo.

Sage Therapeutics and Biogen expect to apply to the FDA in 2022.

The number of dropouts and dropouts because of adverse events did not differ between treatments.

Brain development could be impaired due to iron deficiencies, leading to an increased risk of ADHD.

The new hospital featured 50% private rooms, as well as regular cleaning and other preventative measures for C difficile infections.

Some indicators of suboptimal response included discontinuation of anti-TNF therapy for patients with ulcerative colitis and IBD-related hospitalization for patients with Crohn’s disease.